HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Using ibrutinib in earlier lines of treatment results in better outcomes for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

AuthorsJennifer Woyach, Alessandra Tedeschi, Talha Munir, Tanya Siddiqi, Peter Hillmen, John C Byrd, Paolo Ghia, Stephen P Mulligan, Sandra Dai, Carlos I Amaya-Chanaga, James P Dean, Susan M O'Brien, Paul M Barr
JournalLeukemia & lymphoma (Leuk Lymphoma) Vol. 62 Issue 13 Pg. 3278-3282 (12 2021) ISSN: 1029-2403 [Electronic] United States
PMID34384312 (Publication Type: Letter, Research Support, Non-U.S. Gov't)
Chemical References
  • Piperidines
  • Protein Kinase Inhibitors
  • ibrutinib
  • Adenine
Topics
  • Adenine (analogs & derivatives)
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell (diagnosis, drug therapy, pathology)
  • Piperidines
  • Protein Kinase Inhibitors (adverse effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: